Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with ¹⁷⁷Lu and Conjugated to Peptides

Title:Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with ¹⁷⁷Lu and Conjugated to Peptides

Volume: 8 Issue: 2

Author(s): Guillermina Ferro-Flores, Blanca E. Ocampo-García, Clara L. Santos-Cuevas, Flor de María Ramírez, Erika P. Azorín-Vega and Laura Meléndez-Alafort

Affiliation:

Keywords: Bombesin, cancer thermotherapy, gold nanoparticles, gold nanoparticles-peptides, lutetium-177, RGD, targeted radiotherapy, Tat-peptides.

Abstract: Gold nanoparticles (AuNPs) have been proposed for a variety of medical applications such as localized heat sources for cancer treatment and drug delivery systems. The conjugation of peptides to AuNPs produces stable multimeric systems with target-specific molecular recognition. Lutetium- 177 (¹⁷⁷Lu) has been successfully used in peptide radionuclide therapy. Recently, ¹⁷⁷Lu-AuNPs conjugated to different peptides have been proposed as a new class of theranostic radiopharmaceuticals. These radioconjugates may function simultaneously as molecular imaging agents, radiotherapy systems and thermal-ablation systems. This article covers advancements in the design, synthesis, physicochemical characterization, molecular recognition assessment and preclinical therapeutic efficacy of gold nanoparticles radiolabeled with ¹⁷⁷Lu and conjugated to RGD (-Arg-Gly-Asp-), Lys³-Bombesin and Tat(49-57) peptides.

Cite this article as:

Ferro-Flores Guillermina, Ocampo-García E. Blanca, Santos-Cuevas L. Clara, María Ramírez de Flor, Azorín-Vega P. Erika and Meléndez-Alafort Laura, Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with ¹⁷⁷Lu and Conjugated to Peptides, Current Radiopharmaceuticals 2015; 8 (2) . https://dx.doi.org/10.2174/1874471008666150313115423